C6orf118

Across TCGA pan-cancer cohorts, C6orf118 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated C6orf118 data layer compared with 24 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher C6orf118 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated C6orf118 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

OV, PDAC, and LUAD are the cancer types where C6orf118 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	All	0.804	1.000	.020	12	view →
PDAC	DFS	Median	All	0.254	0.939	.038	6	view →
LUAD	OS	Median	II,III,IV	0.893	0.453	.026	3	view →
HNSC	DFS	Median	III,IV	0.845	1.000	.039	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

C6orf118–OV (DFS)

Open the OV breakdown →